Quick Answer
Outlook Therapeutics, Inc. reported Total Assets of $18.58 million for the year ending 2025.
- Outlook Therapeutics, Inc. showed a decrease of -35.5% in Total Assets from 2024 to 2025.
- This data is from Outlook Therapeutics, Inc.'s annual report (Form 10-K), filed with the SEC on December 19, 2025.
- XBRL data for this metric is available from 2015 to 2025 (11 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q1 2016: $24.83 million | Q2 2016: $32.99 million | Q4 2016: $20.45 million | Q1 2017: $17.46 million | Q2 2017: $17.13 million | Q4 2017: $32.28 million | Q1 2018: $27.79 million | Q2 2018: $34.09 million | Q4 2018: $18.71 million | Q1 2019: $17.17 million | Q2 2019: $33.21 million | Q4 2019: $10.42 million | Q1 2020: $13.17 million | Q2 2020: $30.24 million | Q4 2020: $12.52 million | Q1 2021: $45.11 million | Q2 2021: $32.88 million | Q4 2021: $78.68 million | Q1 2022: $67.69 million | Q2 2022: $38.59 million | Q4 2022: $62.69 million | Q1 2023: $54.02 million | Q2 2023: $44.45 million | Q4 2023: $21.68 million | Q1 2024: $59.03 million | Q2 2024: $47.09 million | Q4 2024: $17.01 million | Q1 2025: $19.08 million | Q2 2025: $22.39 million | Q3 2025: $18.58 million | Q4 2025: $18.24 million.
- Over the full 11 years of available data (2015 to 2025), Outlook Therapeutics, Inc.'s Total Assets has declined by 46.9%.
- Historical annual values: Fiscal year 2025: $18.58 million | Fiscal year 2024: $28.82 million | Fiscal year 2023: $32.30 million | Fiscal year 2022: $28.53 million | Fiscal year 2021: $22.81 million | Fiscal year 2020: $19.73 million | Fiscal year 2019: $17.13 million | Fiscal year 2018: $22.28 million | Fiscal year 2017: $20.73 million | Fiscal year 2016: $25.41 million | Fiscal year 2015: $35.01 million.
- Data sourced from SEC EDGAR public filings as of August 7, 2026.
Last verified: